These findings provide a rationale to explain the effects previously observed by López-Cobo et al. who found that HDACI sensitize tumor cells bearing the BRAF-V600E mutation to the effect of BRAF inhibitors [30]. This evidence concerns the gene BRAF and neoplasm.